TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 1 to the Collaboration and License Agreement is made and effective as of February 12, 2015 by and between Crucell Holland B.V. (“Crucell”) and Bavarian Nordic A/S (“BN”).
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 2 (this “Amendment”), dated as of July 27, 2023 (“Amendment 2 Effective Date”), between Blueprint Medicines Corporation (“Blueprint”) and Oncopia Therapeutics, Inc. d/b/a Proteovant Therapeutics, Inc. (“Proteovant”) amends that certain Collaboration and License Agreement, dated February 26, 2022 by and between Blueprint and Proteovant, as earlier amended on June 5, 2023 (the “Agreement”). Blueprint and the Proteovant are each referred to herein as a “Party” and, collectively, as the “Parties.” Capitalized terms used and not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 1 to Collaboration and License Agreement (“First Amendment”) is made and entered into effective as of December 17, 2021 (“First Amendment Effective Date”) by and between BicycleTx Limited, a company incorporated in England and Wales with a place of business at Building 900, Babraham Research Campus, Cambridge CB22 3AT, UK (“BicycleTx”), and Ionis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 0000 Xxxxxxx Xxxxx, Xxxxxxxx, Xxxxxxxxxx 00000, XXX (“Ionis”). BicycleTx and Ionis are referred to herein individually as a “Party” and collectively as the “Parties”.
TO COLLABORATION AND LICENSE AGREEMENT is executed by the authorized representatives of the Parties as of the First Amendment Effective Date. BICYCLETX LIMITED IONIS PHARMACEUTICALS, INC. By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx Title: Chief Operating Officer (COO) By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx Title: CEO Execution Version Schedule 1 Additional Activities [***]
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 4 to the Collaboration and License Agreement (this "Amendment") is made and entered into as of January 29, 2018 (“Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 0-0-0 Xxxxxxxxx, Xxxxxxx-xx, Xxxxx, 000- 0000, Xxxxx ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Xxxxxxxx, Xxxxxx, Xxxxxxxxxx 00000, XXX ("UGNX'').
TO COLLABORATION AND LICENSE AGREEMENT is executed by the authorized representatives of the Parties as of the Third Amendment Effective Date. BICYCLETX LIMITED IONIS PHARMACEUTICALS, INC. By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx Title: CTO By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx Title: CEO CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Schedule 1 Further Additional Activities [***]
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 3 to Collaboration and License Agreement (“Third Amendment”) is made and entered into effective as of 27th April 2023 (“Third Amendment Effective Date”) by and between BicycleTx Limited, a company incorporated in England and Wales with a place of business at Blocks A & B, Portway Building Granta Park, Great Abington, Cambridge, United Kingdom, CB21 6GS (“BicycleTx”), and Ionis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 0000 Xxxxxxx Xxxxx, Xxxxxxxx, Xxxxxxxxxx 00000, XXX (“Ionis”). BicycleTx and Ionis are referred to herein individually as a “Party” and collectively as the “Parties”.
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 1 to the Collaboration and License Agreement (“Amendment No. 1”) is made and effective as of March 2, 2006 (the “Amendment Effective Date”) by and between INFINITY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 000 Xxxxxxxx Xxxxx, Xxxxxxxxx, Xxxxxxxxxxxxx 00000 (“Infinity”) and XXXXXXX & XXXXXXX PHARMACEUTICAL RESEARCH & DEVELOPMENT, a division of XXXXXXX PHARMACEUTICA N.V., a Belgian business corporation organized and existing under the laws of Belgium with registration number RPR 0403.834.160, VAT No. BE-403.834.160, and with registered office at X-0000 Xxxxxx, Xxxxxxx, Turnhoutseweg 30 (“JJPRD”).
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 1 to Collaboration and License Agreement (this “Amendment No. 1”) is made and effective as of May 1, 2015, by and between Proteostasis Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 000 Xxxxxxxxxx Xxxxxx, 0xx Xxxxx, Xxxxxxxxx, XX 00000 (“PTI”) and Astellas Pharma Inc., a Japanese corporation having its principal place of business at 5-1 Xxxxxxxxxx-Xxxxxx 0-Xxxxx, Xxxx-xx, Xxxxx 000-0000, Xxxxx (“Astellas”). Each of Astellas and PTI is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. Reference is hereby made to that certain Collaboration and License Agreement dated November 4, 2014, by and between the Parties (the “Agreement”). Capitalized terms used, but not defined herein shall have the meanings ascribed to such terms in the Agreement.
TO COLLABORATION AND LICENSE AGREEMENT. This Amendment No. 1 to Collaboration and License Agreement (this "Amendment"), effective as of March 10, 2020 ("Amendment Effective Date"), amends that certain Collaboration and License Agreement, effective September 10, 2018 (the "CLA"), by and between Gilead Sciences, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal plate of business at 000 Xxxxxxxx Xxxxx, Xxxxxx Xxxx, Xxxxxxxxxx 00000 ("Gilead"), and Precision Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 000 Xxxx Xxxxxxxxx Xx., Suite A-100, Durham, North Carolina 27701 ("Precision"). Gilead and Precision are sometimes referred to herein individually as a "Party" and collectively as the "Parties." All capitalized terms not otherwise defined in this Amendment shall have the meaning set forth in the CLA.
